ELAVL4 and hepatocellular carcinoma: Elavl4 is considered a potential oncogene in glioblastoma because it stabilizes pro-survival mRNAs, while HuR (Elavl1) promotes tumour progression in hepatocellular carcinoma and gastric cancer, with its high cytoplasmic expression linked to poor prognosis [139].